Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | TP53 |
| Variant | Y220C |
| Impact List | missense |
| Protein Effect | loss of function |
| Gene Variant Descriptions | TP53 Y220C is a hotspot mutation that lies within the DNA-binding domain (PMID: 17401432). Y220C results in decreased DNA binding, reduced Tp53 transcriptional activity, leads to resistance to apoptosis and failure of G1 arrest in cell culture (PMID: 16861262, PMID: 23630318, PMID: 31395785). |
| Associated Drug Resistance | |
| Category Variants Paths |
TP53 mutant TP53 exon6 TP53 Y220C TP53 mutant TP53 inact mut TP53 Y220C |
| Transcript | NM_000546.6 |
| gDNA | chr17:g.7674872T>C |
| cDNA | c.659A>G |
| Protein | p.Y220C |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_000546 | chr17:g.7674872T>C | c.659A>G | p.Y220C | RefSeq | GRCh38/hg38 |
| NM_000546.5 | chr17:g.7674872T>C | c.659A>G | p.Y220C | RefSeq | GRCh38/hg38 |
| NM_001407264.1 | chr17:g.7674872T>C | c.659A>G | p.Y220C | RefSeq | GRCh38/hg38 |
| NM_001126114.2 | chr17:g.7674872T>C | c.659A>G | p.Y220C | RefSeq | GRCh38/hg38 |
| NM_000546.6 | chr17:g.7674872T>C | c.659A>G | p.Y220C | RefSeq | GRCh38/hg38 |
| NM_001407270.1 | chr17:g.7674872T>C | c.659A>G | p.Y220C | RefSeq | GRCh38/hg38 |
| NM_001126112.3 | chr17:g.7674872T>C | c.659A>G | p.Y220C | RefSeq | GRCh38/hg38 |
| NM_001407262.1 | chr17:g.7674872T>C | c.659A>G | p.Y220C | RefSeq | GRCh38/hg38 |
| NM_001126113.3 | chr17:g.7674872T>C | c.659A>G | p.Y220C | RefSeq | GRCh38/hg38 |
| NM_001126112 | chr17:g.7674872T>C | c.659A>G | p.Y220C | RefSeq | GRCh38/hg38 |
| NM_001126113 | chr17:g.7674872T>C | c.659A>G | p.Y220C | RefSeq | GRCh38/hg38 |
| NM_001126113.2 | chr17:g.7674872T>C | c.659A>G | p.Y220C | RefSeq | GRCh38/hg38 |
| NM_001407268.1 | chr17:g.7674872T>C | c.659A>G | p.Y220C | RefSeq | GRCh38/hg38 |
| NM_001126114.3 | chr17:g.7674872T>C | c.659A>G | p.Y220C | RefSeq | GRCh38/hg38 |
| NM_001407266.1 | chr17:g.7674872T>C | c.659A>G | p.Y220C | RefSeq | GRCh38/hg38 |
| NM_001126114 | chr17:g.7674872T>C | c.659A>G | p.Y220C | RefSeq | GRCh38/hg38 |
| NM_001126112.2 | chr17:g.7674872T>C | c.659A>G | p.Y220C | RefSeq | GRCh38/hg38 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07060989 | Phase Ib/II | NTS071 | A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (NTS071) | Not yet recruiting | USA | 1 |
| NCT04585750 | Phase Ib/II | PC14586 + Pembrolizumab PC14586 | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | AUS | 2 |
| NCT06616636 | Phase I | Azacitidine + PC14586 Azacitidine + PC14586 + Venetoclax | A Phase Ib Study of Rezatapopt in Combination with Azacitidine or Azacitidine and Venetoclax in Patients with TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome) | Recruiting | USA | 0 |
| NCT06386146 | Phase Ib/II | JAB-30355 | JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation | Recruiting | USA | 1 |